KalVista (NASDAQ: KALV) CFO details RSU vesting and sell-to-cover sale
Rhea-AI Filing Summary
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported RSU vesting and a related tax sale. On February 21, 2026, he acquired 5,000 shares of Common Stock at $0.00 per share through the exercise and settlement of 5,000 Restricted Stock Units, each RSU converting into one share for no consideration. On February 23, 2026, he sold 1,767 shares of Common Stock in open-market transactions at a weighted-average price of $15.5668 per share to cover tax withholding obligations under a non-discretionary sell-to-cover arrangement. Following these transactions, he directly held 13,762 shares of Common Stock and 60,000 RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,767 shares ($27,507)
Net Sell
3 txns
Insider
Piekos Brian
Role
Chief Financial Officer
Sold
1,767 shs ($28K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,767 | $15.5668 | $28K |
| Exercise | Restricted Stock Unit | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 13,762 shares (Direct);
Restricted Stock Unit — 60,000 shares (Direct)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5253 to $15.56698 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did KalVista (KALV) CFO Brian Piekos report?
KalVista CFO Brian Piekos reported vesting of 5,000 Restricted Stock Units and their settlement into 5,000 shares of Common Stock, plus a related sale of 1,767 shares to cover tax withholding obligations. All transactions were reported as directly owned, non-derivative and derivative entries.
What Restricted Stock Unit activity did KalVista (KALV) disclose for its CFO?
The filing shows 5,000 Restricted Stock Units exercised and converted into 5,000 shares of Common Stock for no cash consideration. Each RSU represents a contingent right to receive one share upon settlement, and vesting follows a scheduled quarterly pattern tied to continued service.
What is the vesting schedule for the KalVista (KALV) CFO’s RSUs?
The RSU vesting schedule provides that three-sixteenths of the underlying shares vested on November 21, 2025, with one-sixteenth vesting on each quarterly anniversary thereafter. Vesting continues only so long as the grantee’s service with KalVista, as defined in the applicable equity plan, does not terminate.